Teva Pharmaceutical Industries Limited TEVA

Set alert

Price alert · TEVA

All alert types
40.70 USD -1.39 -3.30%

At close

40.33 -0.37 -0.91%

Pre-market · Nov 3, 6:15 AM ET

Bid
40.52 × 200
Ask
40.80 × 400
40.63 Day range 42.00
20.11 52-week range 42.59
YTD
+30.41%
1 year
+98.73%
Open
41.12
Prev close
42.09
Mkt cap
47.47B
Vol
10.59M
Avg vol
5.53M
EPS
0.60
P/E
67.83
Div yield
0.00%
More statistics
Low
40.63
High
42.00
Forward P/E
13.18
Beta
0.84
Short ratio
4.40
Inst. own
30.06%
Dividend
0.00
Ex-div date
Nov 27, 2017
Earnings
Nov 3, 2026
50-d avg
39.09
200-d avg
34.58
1y target
47.58

MAX chart

Chart tools
Interval

Events in this range
  • Nov 4, 1999Dividend: 0.053
  • Nov 7, 2002Dividend: 0.09
  • May 5, 2005Dividend: 0.069
  • Nov 2, 2007Dividend: 0.101
  • Aug 1, 2008Dividend: 0.13
  • Nov 7, 2008Dividend: 0.117
  • Aug 3, 2009Dividend: 0.154
  • Nov 6, 2009Dividend: 0.158
  • Aug 2, 2010Dividend: 0.181
  • Aug 4, 2011Dividend: 0.235
  • Nov 5, 2025Earnings: 0.78; estimate 0.68; surprise 14.71%
  • Nov 2, 2026Rating: HC Wainwright & Co. · — → Buy
  • Nov 3, 2026Earnings: —; estimate 0.72; surprise —%
Signals (45)
NameDateAgo
RSI: OverboughtNov 1, 20251 year ago
SMA: BullishMay 1, 20242 years ago
SMA: BullishNov 1, 20233 years ago
SMA: BearishFeb 1, 20233 years ago
SMA: BullishNov 1, 20224 years ago
MACD: Buy SignalAug 1, 20215 years ago
RSI: OversoldAug 1, 20179 years ago
SMA: BearishAug 1, 201610 years ago
MACD: Sell SignalAug 1, 201610 years ago
SMA: BearishFeb 1, 201610 years ago
RSI: OverboughtMay 1, 201511 years ago
MACD: Buy SignalMay 1, 201412 years ago
SMA: BullishNov 1, 201313 years ago
SMA: BullishNov 1, 201313 years ago
SMA: BearishMay 1, 201214 years ago
SMA: BullishNov 1, 201115 years ago
SMA: BearishAug 1, 201115 years ago
SMA: BearishFeb 1, 201115 years ago
MACD: Sell SignalNov 1, 201016 years ago
RSI: OverboughtNov 1, 200917 years ago

Newest 20 of 45.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 47.58 +16.9% upside
Target (low)
42.00
Target (mean)
47.58
Target (high)
55.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
  • Strong buy4
  • Buy8
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 13
  • 1 month ago 8

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

TEVA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.73020.60 – 0.890.000.0%4.24B-5.3%10
Next quarter0.754640.68 – 0.970.000.0%4.22B-10.3%10
Current year2.111.91 – 2.940.000.0%16.65B-3.5%13
Next year3.092.86 – 3.352.11+46.6%17.23B+3.5%13

Upgrades and downgrades

The latest rating changes

TEVA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026HC Wainwright & Co.Initiated—Buy
Oct 15, 2026BarclaysMaintainedOverweightOverweight
Oct 12, 2026JP MorganMaintainedOverweightOverweight
Oct 1, 2026TD CowenInitiated—Buy
Sep 23, 2026OppenheimerInitiated—Outperform
Sep 9, 2026Leerink PartnersInitiated—Outperform
Sep 4, 2026UBSMaintainedBuyBuy
Aug 12, 2026BarclaysMaintainedOverweightOverweight
Jul 28, 2026Piper SandlerMaintainedOverweightOverweight
May 6, 2026BarclaysMaintainedOverweightOverweight
Apr 30, 2026JP MorganMaintainedOverweightOverweight
Apr 30, 2026UBSMaintainedBuyBuy
Apr 30, 2026Piper SandlerReiteratedOverweightOverweight
Apr 30, 2026Truist SecuritiesMaintainedBuyBuy
Apr 9, 2026B of A SecuritiesMaintainedBuyBuy
Mar 4, 2026Piper SandlerReiteratedOverweightOverweight
Feb 18, 2026Truist SecuritiesMaintainedBuyBuy
Feb 9, 2026Goldman SachsMaintainedBuyBuy
Jan 30, 2026BarclaysMaintainedOverweightOverweight
Jan 29, 2026ScotiabankMaintainedSector OutperformSector Outperform
Jan 29, 2026Truist SecuritiesMaintainedBuyBuy
Jan 6, 2026JefferiesMaintainedBuyBuy
Dec 22, 2025Piper SandlerMaintainedOverweightOverweight
Dec 19, 2025Goldman SachsMaintainedBuyBuy
Dec 16, 2025JP MorganMaintainedOverweightOverweight
Dec 9, 2025B of A SecuritiesMaintainedBuyBuy
Dec 9, 2025BarclaysInitiated—Overweight
Dec 8, 2025Goldman SachsMaintainedBuyBuy
Dec 5, 2025ScotiabankInitiated—Sector Outperform
Nov 6, 2025JP MorganMaintainedOverweightOverweight